How effective is tofacitinib in treating psoriatic arthritis?

Tofacitinib (Tofacitinib) is an oral small molecule JAK inhibitor developed by Pfizer of the United States. It is one of the first JAK inhibitors approved for the treatment of immune-mediated diseases. It blocks the signaling of multiple pro-inflammatory cytokines by inhibiting JAK1 and JAK3, and has shown good results in the treatment of psoriatic arthritis (PsA). Psoriatic arthritis is an inflammatory joint disease that often coexists with moderate to severe psoriasis. It is characterized by joint pain, swelling, limited function and skin damage. Currently, traditional DMARDs such as methotrexate have limited control effect on some patients, so more precise and effective treatment options are needed.

The efficacy of tofacitinib inPsA has been verified by multiple international multi-center randomized controlled clinical trials. The results of a certain study showed that at 12 weeks, more than 50% of patients treated with tofacitinib reached ACR20 (rheumatology improvement index), which was significantly better than the placebo group. In another study, patients who did not respond to biological agents such as TNF inhibitors also experienced multidimensional improvements in joint inflammation, skin symptoms, fatigue and functional impairment under the intervention of tofacitinib. These clinical data indicate that tofacitinib has good therapeutic potential for both newly treated PsA patients who have not received biological therapy and patients who have failed to respond to biological drugs.

Its advantages also include the oral medication form, which brings convenience to patients in daily management and is easier to adhere to than injectable drugs. It is especially suitable for groups who are resistant to injections or have limited mobility. In terms of skin manifestations, tofacitinib also has a certain alleviation effect on psoriasis rash. Although it is not as powerful as the specialized IL-17 or IL-23 biological agents, it has a comprehensive regulatory effect as a systemic drug.

Reference materials:https://www.xeljanz.com/